Lv42
636 积分 2024-01-26 加入
Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours
20天前
已完结
Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma
1个月前
已完结
Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial
1个月前
已完结
Three-year overall survival in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
1个月前
已完结
Three-year overall survival in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
1个月前
已关闭
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
1个月前
已完结
Anti-vascular endothelial growth factor treatment potentiates immune checkpoint blockade through a BAFF- and IL-12-dependent reprogramming of the TME
2个月前
已完结
Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
2个月前
已完结
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma
2个月前
已完结
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma
2个月前
已完结
皖公网安备34019202002308
